NHWK RSI Chart
Last 30 days
-48.4%
Last 90 days
-64.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 939.7K | 1.5M | 2.2M | 7.0M |
2022 | 1.8M | 1.4M | 935.4K | 386.2K |
2021 | 2.6M | 2.5M | 2.1M | 2.1M |
2020 | 3.2M | 3.5M | 4.3M | 2.9M |
2019 | 5.7M | 4.9M | 3.1M | 3.0M |
2018 | 2.6M | 3.7M | 4.7M | 5.8M |
2017 | 538.0K | 734.4K | 1.1M | 1.3M |
2016 | 43.3K | 142.7K | 242.2K | 341.6K |
2015 | 38.7K | 0 | 0 | 0 |
2014 | 17.7K | 25.3K | 32.9K | 40.6K |
2013 | 0 | 0 | 0 | 10.1K |
2012 | 0 | 0 | 0 | 3.1K |
Which funds bought or sold NHWK recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -13,422 | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -28,660 | 16,683 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -7,552 | 4,395 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -143 | - | -% |
May 15, 2024 | PACIFIC CAPITAL WEALTH ADVISORS, INC | unchanged | - | -4.00 | 2.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 6.97 | -1,777 | 1,153 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | reduced | -38.29 | -11,182 | 3,284 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -27,830 | 16,200 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | reduced | -12.41 | -4,830 | 2,296 | -% |
Unveiling NightHawk Biosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NightHawk Biosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
NightHawk Biosciences, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 570.4% | 4,848,034 | 723,126 | 657,778 | 765,900 | 63,917 | 58,861 | 50,981 | 212,418 | 613,100 | 501,567 | 459,494 | 538,645 | 603,192 | 849,732 | 593,165 | 901,880 | 1,999,116 | 6,439 | 342,487 | 701,062 | 2,058,136 |
Costs and Expenses | -16.2% | 9,876,199 | 11,782,921 | 14,973,599 | 13,801,388 | 13,171,099 | 10,599,434 | 9,764,061 | 7,688,970 | - | 8,066,635 | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | 9,764,061 | 7,688,970 | 14,110,758 | 8,066,635 | 7,174,559 | 8,179,893 | 7,629,950 | 9,980,856 | 5,435,471 | 6,026,054 | 5,402,679 | 6,361,492 | 5,396,600 | 6,634,138 | 7,604,636 |
S&GA Expenses | 2.3% | 6,220,541 | 6,082,539 | 7,393,197 | 6,820,550 | 6,728,141 | 4,838,169 | 4,890,544 | 3,776,623 | 5,817,226 | 3,390,093 | 2,853,265 | 4,767,645 | 3,283,021 | 6,579,193 | 1,801,674 | 3,270,548 | 2,229,819 | 1,993,136 | 1,860,459 | 3,347,601 | 2,298,107 |
R&D Expenses | -44.2% | 2,877,614 | 5,155,359 | 5,732,961 | 6,995,848 | 6,536,663 | 5,379,780 | 4,726,517 | 3,933,347 | 4,451,194 | 4,381,542 | 4,216,294 | 3,406,248 | 4,192,929 | 3,172,663 | 2,790,797 | 2,782,506 | 3,287,860 | 3,129,356 | 3,424,141 | 3,172,247 | 5,476,529 |
EBITDA Margin | 73.8% | -5.33 | -20.35 | -29.46 | -45.33 | -101 | -44.03 | -27.94 | -19.51 | -16.28 | -12.98 | -11.73 | -10.34 | -8.65 | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | -191,000 | - | - | - | 42,697 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | -571,120 | - | - | 37,063 | -3,326,000 | - | - | - | - | - | - | - | - | - | - | - | - | 45,178 | -320,253 |
Earnings Before Taxes | 54.5% | -5,103,200 | -11,206,263 | -14,532,822 | -12,895,136 | -13,142,953 | -10,609,762 | -10,263,910 | -8,189,798 | -13,754,840 | -7,548,225 | -6,620,576 | -7,623,140 | -6,554,718 | -8,916,433 | -4,536,818 | -6,373,420 | -3,289,817 | -6,330,913 | -4,944,905 | -5,773,903 | -5,447,774 |
EBT Margin | 73.3% | -6.25 | -23.42 | -33.10 | -49.92 | -109 | -45.78 | -28.85 | -20.21 | -16.82 | -13.48 | -12.12 | -10.69 | -8.95 | - | - | - | - | - | - | - | - |
Net Income | 58.8% | -5,408,035 | -13,132,470 | -13,892,016 | -12,784,647 | -15,224,483 | -13,258,350 | -6,831,286 | -8,120,587 | -13,563,373 | -7,432,720 | -6,543,197 | -7,532,178 | -6,451,592 | -8,851,609 | -4,454,430 | -6,292,106 | -3,336,624 | -6,194,598 | -4,770,870 | -5,715,476 | -4,938,300 |
Net Income Margin | 74.0% | -6.46 | -24.89 | -35.67 | -51.19 | -112 | -44.66 | -26.09 | -19.96 | -16.60 | -13.30 | -11.99 | -10.56 | -8.84 | - | - | - | - | - | - | - | - |
Free Cashflow | 86.9% | -1,210,563 | -9,267,625 | -7,620,202 | -15,419,762 | -8,689,252 | -12,349,824 | 6,526,130 | -11,305,416 | -11,911,103 | -13,472,956 | -9,436,176 | -5,213,384 | -6,459,424 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -27.0% | 51,038 | 69,915 | 80,184 | 91,518 | 104,397 | 119,912 | 131,855 | 114,267 | 120,961 | 132,655 | 138,790 | 144,470 | 124,195 | 129,710 | 58,153 | 37,821 | 25,957 | 24,452 | 29,703 | 33,898 | 37,764 |
Current Assets | -80.3% | 4,761 | 24,180 | 22,782 | 34,358 | 50,054 | 66,474 | 79,389 | 86,578 | 99,331 | 111,831 | 124,759 | 133,878 | 113,794 | 119,142 | 47,601 | 27,127 | 15,209 | 15,790 | 20,238 | 24,406 | 28,714 |
Cash Equivalents | -90.9% | 185 | 2,043 | 5,837 | 7,827 | 3,192 | 13,658 | 10,243 | 14,585 | 8,054 | 7,882 | 21,567 | 31,157 | 10,932 | 24,808 | 20,668 | 20,739 | 9,040 | 9,334 | 13,828 | 17,897 | 22,154 |
Inventory | - | 909 | - | - | - | - | - | 5,844 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -5.9% | 17,587 | 18,684 | 19,111 | 19,431 | 20,439 | 20,731 | 5,253 | 3,099 | 2,158 | 1,767 | 4,146 | 968 | 676 | 720 | 669 | 706 | 559 | 610 | 567 | 621 | 643 |
Goodwill | - | - | - | 3,873 | 3,302 | 3,302 | 3,215 | 5,068 | - | - | 1,452 | 1,452 | 1,452 | 1,452 | 1,452 | 1,452 | 1,452 | 1,452 | 1,452 | 2,189 | 2,189 | 2,189 |
Liabilities | -37.6% | 22,743 | 36,469 | 33,117 | 31,179 | 31,960 | 33,713 | 33,141 | 9,568 | 8,928 | 8,790 | 8,317 | 8,010 | 8,701 | 8,812 | 11,017 | 11,290 | 12,799 | 8,278 | 7,747 | 7,422 | 7,521 |
Current Liabilities | -58.8% | 10,100 | 24,488 | 15,341 | 17,479 | 18,037 | 14,451 | 15,132 | 5,315 | 4,721 | 3,290 | 3,352 | 3,046 | 3,657 | 3,802 | 6,218 | 6,937 | 8,435 | 4,794 | 4,500 | 4,283 | 4,872 |
Shareholder's Equity | -13.5% | 31,397 | 36,293 | 47,067 | 60,339 | 73,923 | 87,539 | 99,964 | 104,698 | 112,034 | 123,865 | 130,472 | 136,460 | 115,494 | 120,898 | 47,136 | 26,531 | 13,158 | 16,173 | 21,955 | 26,476 | 30,243 |
Retained Earnings | -2.2% | -254,400 | -249,000 | -235,800 | -221,938 | -209,153 | 193,929 | 180,671 | -173,800 | -165,718 | -152,200 | -144,700 | -138,200 | -130,647 | -124,195 | -115,300 | -110,889 | -104,597 | -101,261 | -95,066 | -90,295 | -84,580 |
Additional Paid-In Capital | 0.2% | 285,713 | 285,090 | 284,454 | 283,785 | 283,019 | 281,320 | 280,603 | 279,800 | 278,890 | 277,098 | 276,225 | 275,619 | 247,048 | 245,741 | 163,008 | 137,693 | 118,180 | 117,836 | 117,351 | 116,943 | 114,883 |
Shares Outstanding | 0.5% | 26,219 | 26,082 | 26,047 | 26,049 | 25,661 | 25,613 | 25,598 | 25,594 | 25,650 | 25,138 | 25,137 | 24,200 | 22,832 | - | - | - | - | - | - | - | - |
Minority Interest | -9.0% | -3,102 | -2,845 | -1,666 | -1,596 | -1,486 | -1,340 | -1,250 | -1,143 | -1,074 | -1,029 | -913 | -836 | -745 | -642 | -577 | -495 | -413 | -460 | -324 | -150 | -46.60 |
Float | - | - | - | 16,554 | - | - | - | 65,407 | - | - | - | 169,017 | - | - | - | 89,997 | - | - | - | 23,393 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 87.2% | -1,077 | -8,451 | -8,208 | -13,794 | -7,842 | 3,571 | 8,786 | -10,214 | -11,389 | -15,736 | -6,152 | -4,849 | -6,442 | -5,503 | -4,294 | -5,780 | -252 | -4,347 | -4,061 | -4,175 | -5,998 |
Share Based Compensation | -12.0% | 528 | 600 | 700 | 800 | 1,681 | 700 | 800 | 910 | 1,782 | 900 | 600 | 2,898 | 353 | 4,700 | 400 | 900 | 324 | 500 | 400 | 2,060 | 166 |
Cashflow From Investing | -73.1% | 2,099 | 7,815 | 8,836 | 13,486 | 7,369 | -148 | -13,027 | 16,798 | 11,622 | 2,121 | -3,405 | -567 | -8,361 | -66,311 | -20,691 | -54.85 | -42.85 | -132 | -37.07 | -81.38 | -5,616 |
Cashflow From Financing | -3866.9% | -6,201 | 165 | -2,617 | -298 | -4,761 | -34.53 | -55.95 | -55.19 | -61.51 | -61.16 | -30.17 | 25,643 | 923 | 75,954 | 24,900 | 17,551 | -1.97 | -1* | - | - | 12,771 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Revenue | $ 6,994,838 | $ 370,176 |
Operating expenses: | ||
Cost of revenues | 2,736,998 | 81,295 |
Research and development | 20,119,791 | 20,223,495 |
Selling, general and administrative | 26,170,221 | 20,130,546 |
In-process research and development impairment | 3,500,000 | |
Change in fair value of contingent consideration | (3,342,515) | |
Total operating expenses | 49,027,010 | 40,592,821 |
Operating loss | (42,032,172) | (40,222,645) |
Change in fair value of warrant liability | 11,020 | |
Interest income | 457,189 | 987,247 |
Unrealized gain (loss) on short-term investments | 123,044 | (1,701,428) |
Interest expense | (776,838) | (182,509) |
Other expense, net | (104,822) | (482,689) |
Total non-operating loss | (301,427) | (1,368,359) |
Net loss before income taxes from continuing operations | (42,333,599) | (41,591,004) |
Income tax benefit | 571,120 | 215,937 |
Net loss from continuing operations | (41,762,479) | (41,375,067) |
Net loss from discontinued operations before income taxes | (5,005,518) | (5,560,130) |
Income tax (expense) benefit from discontinued operations | (65,189) | 3,073,000 |
Net loss from discontinued operations, net of tax benefit | (5,070,707) | (2,487,130) |
Net loss | (46,833,186) | (43,862,197) |
Net loss - non-controlling interest | (1,616,018) | (427,491) |
Net loss attributable to Scorpius Holdings, Inc. | $ (45,217,168) | $ (43,434,706) |
Net loss per share, basic - continuing operations (in dollars per share) | $ (1.54) | $ (1.60) |
Net loss per share, diluted - continuing operations (in dollars per share) | (1.54) | (1.60) |
Net loss per share, basic - discontinued operations (in dollars per share) | (0.19) | (0.10) |
Net loss per share, diluted - discontinued operations (in dollars per share) | (0.19) | (0.10) |
Net loss per share common share attributable to Scorpius Holdings, Inc., basic | (1.74) | (1.70) |
Net loss per share common share attributable to Scorpius Holdings, Inc., diluted | $ (1.74) | $ (1.70) |
Weighted-average common shares outstanding, basic (in shares) | 26,046,594 | 25,606,326 |
Weighted-average common shares outstanding, diluted (in shares) | 26,046,594 | 25,606,326 |
Comprehensive loss from continuing operations: | ||
Net loss | $ (46,833,186) | $ (43,862,197) |
Unrealized (loss) gain on foreign currency translation | (3,047) | 119,865 |
Total comprehensive loss | (46,836,233) | (43,742,332) |
Comprehensive loss attributable to non-controlling interest | (1,616,018) | (427,491) |
Comprehensive loss - Scorpius Holdings, Inc. | $ (45,220,215) | $ (43,314,841) |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 184,925 | $ 3,191,714 |
Short-term investments | 2,206,555 | 35,837,309 |
Accounts receivable | 375,192 | 81,456 |
Grant receivable | 1,524,522 | |
Estimated fair value of contingent consideration receivable, related party | 268,000 | |
Prepaid expenses and other current assets | 817,029 | 1,491,123 |
Inventory | 909,158 | |
Current assets of discontinued operations | 7,928,136 | |
Total Current Assets | 4,760,859 | 50,054,260 |
Property and Equipment, net | 17,587,337 | 20,438,521 |
Operating lease right-of-use asset | 6,041,439 | 5,866,261 |
Finance lease right-of-use asset | 20,473,742 | 15,329,075 |
Other assets | 203,135 | 260,011 |
Deposits | 251,115 | 270,461 |
Contingent earn-out receivable, related party | 1,720,000 | |
Non-current assets of discontinued operations | 12,178,323 | |
Total Assets | 51,037,627 | 104,396,912 |
Current Liabilities | ||
Accounts payable | 4,109,947 | 4,213,732 |
Deferred revenue, current portion | 2,359,441 | 1,585,808 |
Operating lease liability, current portion | 524,208 | 397,855 |
Finance lease liability, current portion | 904,681 | 301,048 |
Accrued expenses and other liabilities | 2,201,861 | 1,916,601 |
Current liabilities of discontinued operations | 9,622,279 | |
Total Current Liabilities | 10,100,138 | 18,037,323 |
Long Term Liabilities | ||
Deferred revenue, net of current portion | 30,000 | 32,500 |
Operating lease liability, net of current portion | 3,597,014 | 3,079,887 |
Financing lease liability, net of current portion | 9,016,140 | 5,520,034 |
Non-current liabilities of discontinued operations | 5,290,500 | |
Total Liabilities | 22,743,292 | 31,960,244 |
Commitments and Contingencies (Note 11 and 15) | ||
Stockholders' Equity | ||
Common stock, $0.0002 par value; 250,000,000 shares authorized, 26,219,461 and 25,661,488 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 5,244 | 5,126 |
Additional paid-in capital | 285,713,238 | 283,019,456 |
Accumulated deficit | (254,370,827) | (209,153,659) |
Accumulated other comprehensive income | 48,877 | 51,924 |
Total Stockholders' Equity - Scorpius Holdings, Inc. | 31,396,532 | 73,922,847 |
Non-Controlling Interest | (3,102,197) | (1,486,179) |
Total Stockholders' Equity | 28,294,335 | 72,436,668 |
Total Liabilities and Stockholders' Equity | $ 51,037,627 | $ 104,396,912 |